| 7813- | ISQ, | Isoquercitrin Played a Neuroprotective Role in Rats After Cerebral Ischemia/Reperfusion Through Up-Regulating Neuroglobin and Anti-Oxidative Stress |
| - | in-vivo, | Stroke, | NA |
| 7812- | ISQ, | Isoquercitrin promotes ferroptosis and oxidative stress in nasopharyngeal carcinoma via the AMPK/NF-κB pathway |
| - | vitro+vivo, | NPC, | CNE1 | - | in-vitro, | NPC, | HNE1 |
| 7811- | ISQ, | Isoquercitrin alleviates OGD/R-induced oxidative stress and impaired mitochondrial biogenesis in SH-SY5Y cells via the NRF1/TFAM pathway |
| - | in-vitro, | Stroke, | SH-SY5Y |
| 7810- | ISQ, | Isoquercitrin Inhibits Lung Cancer Cell Growth Through Triggering Pyroptosis and Ferroptosis |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B |
| 7847- | ISQ, | Research on the bioactivity of isoquercetin extracted from marestail on bladder cancer EJ cell and the mechanism of its occurrence |
| - | in-vitro, | Bladder, | NA |
| 7792- | ISQ, | Isoquercitrin suppresses colon cancer cell growth in vitro by targeting the Wnt/β-catenin signaling pathway |
| - | in-vitro, | CRC, | SW48 | - | in-vitro, | CRC, | DLD1 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | IEC-18 |
| 7793- | ISQ, | Apoptosis triggered by isoquercitrin in bladder cancer cells by activating the AMPK-activated protein kinase pathway |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 7800- | ISQ, | Isoquercitrin Attenuates Oxidative Liver Damage Through AMPK-YAP Signaling: An Integrative In Silico, In Vitro, and In Vivo Study |
| - | vitro+vivo, | Nor, | HepG2 |
| 7799- | ISQ, | Acer okamotoanum and isoquercitrin improve cognitive function via attenuation of oxidative stress in high fat diet- and amyloid beta-induced mice |
| - | in-vivo, | AD, | NA |
| 7798- | ISQ, | MOR, | Several targets involved in Alzheimer's disease amyloidogenesis are affected by morin and isoquercitrin |
| - | in-vitro, | AD, | NA |
| 7797- | ISQ, | Isoquercitrin Suppresses Esophageal Squamous Cell Carcinoma (ESCC) by Inducing Excessive Autophagy and Promoting Apoptosis via the AKT/mTOR Signaling Pathway |
| - | vitro+vivo, | ESCC, | KYSE-510 | - | in-vitro, | ESCC, | KYSE450 |
| 7796- | ISQ, | Isoquercitrin restrains the proliferation and promotes apoptosis of human osteosarcoma cells by inhibiting the Wnt/β-catenin pathway |
| - | vitro+vivo, | OS, | 143B | - | in-vitro, | OS, | U2OS |
| 7794- | ISQ, | Isoquercitrin induces apoptosis and autophagy in hepatocellular carcinoma cells via AMPK/mTOR/p70S6K signaling pathway |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | HUH7 |
| 7845- | ISQ, | Isoquercitrin, ingredients in Tetrastigma hemsleyanum Diels et Gilg, inhibits hepatocyte growth factor/scatter factor-induced tumor cell migration and invasion |
| - | vitro+vivo, | Bladder, | NBT-II |
| 7844- | ISQ, | Isoquercetin upregulates antioxidant genes, suppresses inflammatory cytokines and regulates AMPK pathway in streptozotocin-induced diabetic rats |
| - | NA, | Diabetic, | NA |
| 7843- | ISQ, | In vitro response of human ovarian cancer cells to dietary bioflavonoid isoquercitrin |
| - | in-vitro, | Ovarian, | OVCAR-3 |
| 7841- | ISQ, | Enzymatically modified isoquercitrin improves endothelial function in volunteers at risk of cardiovascular disease |
| - | Human, | CardioV, | NA |
| 7840- | ISQ, | Neuroprotective effects of isoquercitrin in diabetic neuropathy via Wnt/β-catenin signaling pathway inhibition |
| - | in-vivo, | Diabetic, | NA |
| 7838- | ISQ, | Protective effects of isoquercitrin on streptozotocin‐induced neurotoxicity |
| - | in-vivo, | AD, | NA |
| 7837- | ISQ, | Isoquercitrin Delays Denervated Soleus Muscle Atrophy by Inhibiting Oxidative Stress and Inflammation |
| - | in-vivo, | Nor, | NA |
| 7836- | ISQ, | An Isoquinolinium Dual Inhibitor of Cholinesterases and Amyloid β Aggregation Mitigates Neuropathological Changes in a Triple-Transgenic Mouse Model of Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| - | in-vitro, | AD, | HT22 |
| 7846- | ISQ, | Ninety-day toxicity and single-dose toxicokinetics study of alpha-glycosyl isoquercitrin in Sprague-Dawley rats |
| - | in-vivo, | Nor, | NA |
| 7848- | ISQ, | Review of anticancer mechanisms of isoquercitin |
| - | Review, | Var, | NA |
| 7559- | ISQ, | Difference in absorption of the two structurally similar flavonoid glycosides, hyperoside and isoquercitrin, in rats |
| - | in-vivo, | Nor, | NA |
| 8011- | itraC, | Anti-proliferation of breast cancer cells with itraconazole: Hedgehog pathway inhibition induces apoptosis and autophagic cell death |
| - | vitro+vivo, | BC, | MCF7 | - | vitro+vivo, | BC, | SkBr3 |
| 8010- | itraC, | Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells |
| - | vitro+vivo, | GC, | MKN45 |
| 8012- | itraC, | Effects and mechanism of itraconazole on prostate cancer PC-3 cell apoptosis |
| - | in-vitro, | Pca, | PC3 |
| 7982- | itraC, | Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis |
| - | in-vitro, | Nor, | HUVECs | - | in-vitro, | Lung, | A549 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HEK293 |
| 7983- | itraC, | Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells |
| - | in-vitro, | Nor, | HUVECs |
| 7984- | itraC, | The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells |
| 8009- | itraC, | Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways |
| - | vitro+vivo, | Melanoma, | SK-MEL-28 | - | vitro+vivo, | Melanoma, | A375 |
| 7997- | itraC, | Anti-fungal drug itraconazole exerts anti-cancer effects in oral squamous cell carcinoma via suppressing Hedgehog pathway |
| - | vitro+vivo, | SCC, | NA |
| 7996- | itraC, | Itraconazole in the Treatment of Aberrantly Active Hedgehog and/or PI3K Recurrent Ovarian Cancer |
| - | Trial, | Ovarian, | NA |
| 7995- | itraC, | Repurposing itraconazole in clinical dermato-oncology beyond conventional antifungal use: a review |
| - | Review, | Var, | NA |
| 7994- | itraC, | From fungus fighter to cancer slayer: itraconazole as a multifaceted candidate for drug-resistant prostate cancer |
| - | Review, | Pca, | NA |
| 7993- | itraC, | Preclinical evaluation of itraconazole in docetaxel-resistant prostate cancer xenograft models |
| - | in-vivo, | Pca, | NA |
| 7992- | itraC, | Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs |
| 7991- | itraC, | A Phase II Trial of Perioperative Oral Itraconazole for the Management of Low-Risk Basal Cell Carcinoma |
| - | Trial, | BCC, | NA |
| 7990- | itraC, | A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole-A Single-Institution Randomized Placebo-Controlled Trial |
| - | Trial, | Ovarian, | NA |
| 7989- | itraC, | Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer |
| - | Trial, | NSCLC, | NA |
| 7985- | itraC, | Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking |
| - | vitro+vivo, | GBM, | U87MG | - | vitro+vivo, | GBM, | C6 |
| 7988- | itraC, | Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study |
| - | Trial, | Pca, | NA |
| 7987- | itraC, | Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer |
| - | Trial, | Pca, | NA |
| 7998- | itraC, | Itraconazole targets cell cycle heterogeneity in colorectal cancer |
| - | vitro+vivo, | CRC, | NA |
| 7999- | itraC, | Itraconazole-Induced Inhibition on Human Esophageal Cancer Cell Growth Requires AMPK Activation |
| - | vitro+vivo, | ESCC, | NA |
| 8000- | itraC, | The anti-cancer effects of itraconazole in epithelial ovarian cancer |
| - | NA, | Ovarian, | NA |
| 8001- | itraC, | Repurposing itraconazole as an anticancer agent |
| - | Review, | Var, | NA |
| 8013- | itraC, | High-dose itraconazole as a non-castrating therapy for a patient with biochemically-recurrent prostate cancer |
| - | Case Report, | Pca, | NA |
| 7986- | itraC, | Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma |
| - | Trial, | BCC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid